Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors FasL and ACR2B, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 17/September/2017, 11.48 pm

Natural product-based combinatorial therapy for Lifespan extension: A therapeutic mix encompassing Hesperidin, DIM, and Cholecalciferol activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via up regulation of its target gene ATG5 (Autophagy related 5), 17/September/2017, 12.26 am
September 16, 2017
Natural product-derived therapy for anxiety and depression: Trans-astaxanthin, isolated from Green algae among others, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 17/September/2017, 11.52 pm
September 17, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggests that Myrtenal inhibits tumor cell proliferation. However, the mechanism of action is far from clear.

This study suggests that Myrtenal, by regulating the expression of its target genes, it may increase the expression of tumor suppressors FasL and ACR2B (fig. 1).

[easy_payment currency=”USD”]

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. 

Thus,  Myrtenal or its analogues, either alone or in combination with other anticancer drugs, may be advised for metastatic cancer patients to (i) increase the expression of metastasis/tumor suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of cancer therapy. Together, oncologists may consider experimenting the use of Myrtenal in the treatment of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $10#

Fig1. Mechanistic insights into how the natural product-derived compound Myrtenal functions as an anti-metastasis agent. Myrtenal increases the expression of tumor suppressors FasL and ACR2B via up regulation of its target genes.

Undisclosed mechanistic information: How Myrtenal increases the expression of tumor suppressors FasL and ACR2B

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors FasL and ACR2B, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 17/September/2017, 11.48 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.